After BMO Capital and RBC Capital gave ObsEva SA (NASDAQ: OBSV) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA (NASDAQ: OBSV) today and set a price target of $30. The company’s shares closed on Friday at $16.33.
Selvaraju wrote:
“Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach currently ascribes $1.08B to OBE2109 (as opposed to the prior $1B valuation for this candidate) and $170M to nolasiban. We utilize an 85% probability of success for OBE2109 vs. the previous 80%, reflecting the risk mitigation associated with the release of positive data from the EDELWEISS Phase 2b trial. The current total valuation of $1.25B translates to $30.00 per share, assuming roughly 42M fully-diluted shares outstanding as of mid-2019.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.2% and a 44.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
ObsEva SA has an analyst consensus of Strong Buy, with a price target consensus of $30.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.35 and a one-year low of $6.15. Currently, ObsEva SA has an average volume of 126.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
